Marie joined the board of Hoba Therapeutics in 2023. She brings more than a decade of scientific experience, in both the pharmaceutical industry and academia. Marie is currently a senior associate at Novo Holdings, where she is responsible for company creation and early investments, particularly in the cardiometabolic disease space. She also serves as an observer on the Board of Directors of Acesion Pharma. Marie has a DPhil in Physiology, Anatomy and Genetics from the University of Oxford (Lincoln College), and a bachelor’s degree in biomedical and electrical engineering from Duke University.